menu
    • menu

    Company profile for Oncotelic Therapeutics

    NEW Drugs in Dev: 4
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Oncotelic is an immuno-oncology company dedicated to the development of first in class RNA therapeutics as well as small molecule drugs against cancer and infectious diseases. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-βRNA therapeutic that exhibited single agent activity in relapsed/refractory cancer patients in clinical trial settings. OT-101 also has activity against SARS-CoV...
    Oncotelic is an immuno-oncology company dedicated to the development of first in class RNA therapeutics as well as small molecule drugs against cancer and infectious diseases. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-βRNA therapeutic that exhibited single agent activity in relapsed/refractory cancer patients in clinical trial settings. OT-101 also has activity against SARS-CoV-2. Mateon/Oncotelic is seeking to leverage its deep expertise in drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Oncotelic TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    29397 Agoura road, Suite 107, Agoura hills CA 91301
    Telephone
    Telephone
    6506357000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.oncotelic.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/oncotelic/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/Oncotelic

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    BePharma

    Not Confirmed

    envelop Contact Supplier

    BePharma

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Oncotelic Aligns Key IP with Biotech Trends
    Oncotelic Aligns Key IP with Biotech Trends

    18 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/18/3240210/0/en/Oncotelic-Therapeutics-Inc-OTCQB-OTLC-Key-IP-Portfolio-Advancements-Align-with-Biotech-Asset-Trend.html

    GLOBENEWSWIRE
    18 Feb 2026
    Share Share
    Oncotelic Therapeutics & Sapu Bio Expand Global IP for OT-101
    Oncotelic Therapeutics & Sapu Bio Expand Global IP for OT-101

    12 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/12/3237197/0/en/Oncotelic-Therapeutics-Inc-and-Sapu-Bioscience-Expand-International-IP-Coverage-for-OT-101-Strengthening-CNS-and-Neurology-Commercialization-Pathway.html

    GLOBENEWSWIRE
    12 Feb 2026
    Share Share
    Oncotelic Enters 2026 with Strong Late-Stage Pipeline
    Oncotelic Enters 2026 with Strong Late-Stage Pipeline

    10 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/10/3235316/0/en/Oncotelic-Therapeutics-Inc-Showcases-Multi-Year-Execution-and-Validation-Enters-2026-with-Late-Stage-Momentum-Across-Diversified-Pipeline.html

    GLOBENEWSWIRE
    10 Feb 2026
    Share Share
    Oncotelic Therapeutics & Brush & Key Publish Paper in IJMS
    Oncotelic Therapeutics & Brush & Key Publish Paper in IJMS

    15 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/15/3205570/0/en/Oncotelic-Therapeutics-and-Brush-and-Key-Foundation-Announce-Publication-in-International-Journal-of-Molecular-Sciences-Highlighting-Context-Dependent-Biomarkers-in-Liver-and-Pancr.html

    GLOBENEWSWIRE
    15 Dec 2025
    Share Share
    Oncotelic, Sapu Nano Unveil Deciparticle-Led Cancer Biomarker
    Oncotelic, Sapu Nano Unveil Deciparticle-Led Cancer Biomarker

    04 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/04/3199970/0/en/Oncotelic-and-Sapu-Nano-Announce-DeciparticleTM-Led-Biomarker-Framework-Identifying-Tumors-Most-Likely-to-Respond-to-IV-Sapu003-an-Intravenous-Everolimus-Nanomedicine.html

    GLOBENEWSWIRE
    04 Dec 2025
    Share Share
    IV Sapu003 Shows 67x Lower GI Exposure vs Oral Everolimus
    IV Sapu003 Shows 67x Lower GI Exposure vs Oral Everolimus

    03 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/03/3198954/0/en/Oncotelic-and-Sapu-Nano-Announces-New-PK-Data-Demonstrating-IV-Sapu003-Reduces-GI-Accumulation-of-Everolimus-up-to-67-Fold-Compared-With-Oral-Dosing.html

    GLOBENEWSWIRE
    03 Dec 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search